Literature DB >> 30546880

Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin III for acute coronary syndrome risk.

Jinyang Lu1, Dandan Niu2, Di Zheng1, Quan Zhang1, Wenhua Li1.   

Abstract

The aim of the present study was to observe the role of lipoprotein-associated phospholipase A2 (Lp-PLA2) and antithrombin III (AT-III) in patients with acute coronary syndrome (ACS), and the combination of Global Registry of Acute Coronary Events (GRACE) score to determine the value of coronary heart disease risk stratification. A total of 309 patients admitted to the Affiliated Hospital of Xuzhou Medical University were enrolled. The patients were divided into two groups: The ACS (183 cases) and control (126 cases) groups. Blood levels of Lp-PLA2 and AT-III were measured. Based on GRACE score, the patients with ACS were divided into three subgroups: Low risk (GRACE score ≤108), middle risk (GRACE score 109-140) and high risk (GRACE score >140). The levels of Lp-PLA2 and AT-III were compared among different groups, and based on Gensini score, patients with ACS were divided into four groups by quartiles. Lp-PLA2 levels in the ACS group were significantly increased compared with the control group (P<0.05), but the AT-III levels were decreased compared with the control group (P<0.05). In the ACS group, Lp-PLA2 levels increased sequentially from the low risk to high risk subgroups (all P<0.05); compared with the low risk and middle risk subgroups, the AT-III activity levels were decreased in the high risk subgroup, and the Gensini scores were increased (all P<0.05). In the ACS group, with the increase of Gensini scores, the levels of Lp-PLA2 and AT-III exhibited increasing and decreasing trends, respectively (P<0.05). The logistic regression model demonstrated that Lp-PLA2 [odds ratio (OR) =1.077; P<0.001]; and GRACE score (OR=1.026; P=0.028) were risk factors, while AT-III was a protective factor (OR=0.958; P=0.012) for ACS. Correlation analysis indicated a positive association of Lp-PLA2 level with Gensini scores (r=0.52; P<0.01) and GRACE score (r=0.48; P<0.01), and a negative association between AT-III level and Gensini scores (r=-0.25; P<0.01) and GRACE scores (r=-0.34; P<0.01). The levels of Lp-PLA2 and AT-III exhibited predictive values in patients with ACS, and are associated with the severity of coronary artery stenosis.

Entities:  

Keywords:  GRACE score; acute coronary syndrome; antithrombin III; lipoprotein-associated phospholipase A2

Year:  2018        PMID: 30546880      PMCID: PMC6256189          DOI: 10.3892/br.2018.1162

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  35 in total

1.  Distinct risk profiles of early and advanced atherosclerosis: prospective results from the Bruneck Study.

Authors:  J Willeit; S Kiechl; F Oberhollenzer; G Rungger; G Egger; E Bonora; M Mitterer; M Muggeo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-02       Impact factor: 8.311

2.  Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation.

Authors:  Daniel J D Johnson; Wei Li; Ty E Adams; James A Huntington
Journal:  EMBO J       Date:  2006-04-13       Impact factor: 11.598

Review 3.  The hemostatic system as a regulator of inflammation in atherosclerosis.

Authors:  Miriam Koch; Alma Zernecke
Journal:  IUBMB Life       Date:  2014-12-09       Impact factor: 3.885

Review 4.  Inflammation in atherosclerosis: from pathophysiology to practice.

Authors:  Peter Libby; Paul M Ridker; Göran K Hansson
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

5.  [Antithrombin III activity in long-developing hypercoagulation in animals].

Authors:  V E Pastorova; G G Bazaz'ian; L A Liapina
Journal:  Biull Eksp Biol Med       Date:  1984-11

Review 6.  The hypercoagulable states.

Authors:  A I Schafer
Journal:  Ann Intern Med       Date:  1985-06       Impact factor: 25.391

Review 7.  Phospholipase A2 biochemistry.

Authors:  John E Burke; Edward A Dennis
Journal:  Cardiovasc Drugs Ther       Date:  2008-10-18       Impact factor: 3.727

8.  Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.

Authors:  O D Pedersen; J Gram; J Jespersen
Journal:  Thromb Haemost       Date:  1995-05       Impact factor: 5.249

9.  European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Authors:  Joep Perk; Guy De Backer; Helmut Gohlke; Ian Graham; Zeljko Reiner; W M Monique Verschuren; Christian Albus; Pascale Benlian; Gudrun Boysen; Renata Cifkova; Christi Deaton; Shah Ebrahim; Miles Fisher; Giuseppe Germano; Richard Hobbs; Arno Hoes; Sehnaz Karadeniz; Alessandro Mezzani; Eva Prescott; Lars Ryden; Martin Scherer; Mikko Syvänne; Wilma J M Scholte Op Reimer; Christiaan Vrints; David Wood; Jose Luis Zamorano; Faiez Zannad
Journal:  Int J Behav Med       Date:  2012-12

10.  Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.

Authors:  Anping Cai; Guang Li; Jiyan Chen; Xida Li; Liwen Li; Yingling Zhou
Journal:  BMC Cardiovasc Disord       Date:  2015-02-26       Impact factor: 2.298

View more
  2 in total

1.  Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study.

Authors:  Fumeng Yang; Liping Ma; Lili Zhang; Yilian Wang; Changxin Zhao; Wenjun Zhu; Wei Liang; Qian Liu
Journal:  Heart Vessels       Date:  2019-04-08       Impact factor: 2.037

Review 2.  An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases.

Authors:  Shi-Hui Law; Mei-Lin Chan; Gopal K Marathe; Farzana Parveen; Chu-Huang Chen; Liang-Yin Ke
Journal:  Int J Mol Sci       Date:  2019-03-06       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.